3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Conditions
Infections
2
Wound Infection
1
Surgical Wound Infection
1
Prostatic Neoplasms
1
Laryngeal Neoplasms
1
Bone Neoplasms
1
Interventions
liposomal amphotericin B
2
Voriconazole
2
Ribavirin
2
Levofloxacin
2
Fluconazole
2
Ciprofloxacin
2
Cefazolin
2
telaprevir
1
peginterferon alfa-2a
1
lime
1
human papillomavirus vaccine, L1 type 16, 18
1
amphotericin B, deoxycholate drug combination
1
Vancomycin
1
Valacyclovir
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Trimethoprim
1
Therapeutics
1
Tazobactam
1
Surgical Procedures, Operative
1
Sulfamethoxazole
1
Piperacillin, Tazobactam Drug Combination
1
Piperacillin
1
Palivizumab
1
Olive Oil
1
Ofloxacin
1
Nystatin
1
Moxifloxacin
1
Itraconazole
1
Diet
1
Cefepime
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Infections
×
Cefazolin
×
Clear all
NCT01479283
2021-03-11
PARITY
McMaster University
Phase 3
Completed
602 enrolled
NCT00867295
2010-06-02
TIVAD
Istanbul University
Phase 3
Completed
150 enrolled